The invasive fungal infection requires a long treatment schedule; however, treatment becomes more cumbersome due to the development of resistance. Most antifungal moieties show systemic toxicity upon oral administration, leading to delivery of antifungal moiety via topical route. Eberconazole (EBZ) is a BCS class II drug that has poor solubility and high permeability. It is a broad-spectrum imidazole derivative, which acts as both fungicidal and fungistatic by inhibiting ergosterol synthesis. Various topical creams of EBZ are available in the market, but the lack of a proper dosing schedule and rapid removal leads to poor bioavailability. Niosomes are vesicular carriers that can entrap both hydrophilic and lipophilic drugs. Niosomal formulations have been prepared using Span20 (nonionic surfactant) and cholesterol by thin-film hydration (TFH) technique. During the pre-formulation studies, purity of EBZ was ascertained using FT-IR and melting point studies while standard calibration curve was prepared using UV-visible spectroscopy. The prepared niosomal formulations were characterized for their morphology, entrapment efficiency, particle size, and zeta-potential. The formulation has shown 86 ± 0.85% entrapment efficiency while noisome appeared ring-like structure during its microscopic evaluation. The niosomal formulations were also evaluated for their release and release kinetics using the dialysis bag method. The release profile has shown sustained delivery of EBZ up to 120 hrs. In nutshell, EBZ loaded niosomal formulation will be useful and beneficial as compared to currently available marketed preparations by increasing the bioavailability and decreasing the toxicity due to its sustained release behavior.